DE10102977A1 - Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose - Google Patents
Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von OsteoporoseInfo
- Publication number
- DE10102977A1 DE10102977A1 DE10102977A DE10102977A DE10102977A1 DE 10102977 A1 DE10102977 A1 DE 10102977A1 DE 10102977 A DE10102977 A DE 10102977A DE 10102977 A DE10102977 A DE 10102977A DE 10102977 A1 DE10102977 A1 DE 10102977A1
- Authority
- DE
- Germany
- Prior art keywords
- clc
- nucleic acid
- substances
- chloride
- channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 46
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 239000004480 active ingredient Substances 0.000 title claims description 7
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 108010062745 Chloride Channels Proteins 0.000 claims abstract description 78
- 102000011045 Chloride Channels Human genes 0.000 claims abstract description 78
- 239000000126 substance Substances 0.000 claims abstract description 72
- 101710135663 H(+)/Cl(-) exchange transporter 7 Proteins 0.000 claims abstract description 67
- 102100028685 H(+)/Cl(-) exchange transporter 7 Human genes 0.000 claims abstract description 65
- 102100034477 H(+)/Cl(-) exchange transporter 3 Human genes 0.000 claims abstract description 44
- 101710135680 H(+)/Cl(-) exchange transporter 3 Proteins 0.000 claims abstract description 44
- 102100034472 H(+)/Cl(-) exchange transporter 4 Human genes 0.000 claims abstract description 43
- 101710135668 H(+)/Cl(-) exchange transporter 4 Proteins 0.000 claims abstract description 43
- 102100034473 H(+)/Cl(-) exchange transporter 6 Human genes 0.000 claims abstract description 39
- 101710135664 H(+)/Cl(-) exchange transporter 6 Proteins 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 102100034471 H(+)/Cl(-) exchange transporter 5 Human genes 0.000 claims abstract description 27
- 101710135667 H(+)/Cl(-) exchange transporter 5 Proteins 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 230000000926 neurological effect Effects 0.000 claims abstract description 8
- 208000018360 neuromuscular disease Diseases 0.000 claims abstract description 8
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 7
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 7
- 208000010191 Osteitis Deformans Diseases 0.000 claims abstract description 7
- 208000027868 Paget disease Diseases 0.000 claims abstract description 7
- 208000027202 mammary Paget disease Diseases 0.000 claims abstract description 7
- 210000005036 nerve Anatomy 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 63
- 108091006146 Channels Proteins 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 35
- 150000007523 nucleic acids Chemical group 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 26
- 239000012528 membrane Substances 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 101710091665 Chloride channel protein 1 Proteins 0.000 claims description 14
- 102100023457 Chloride channel protein 1 Human genes 0.000 claims description 14
- 101710091667 Chloride channel protein 2 Proteins 0.000 claims description 14
- 102100023509 Chloride channel protein 2 Human genes 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 10
- 210000004602 germ cell Anatomy 0.000 claims description 10
- 102000018421 Chloride channel ClC-7 Human genes 0.000 claims description 9
- 108050007526 Chloride channel ClC-7 Proteins 0.000 claims description 9
- 230000036961 partial effect Effects 0.000 claims description 8
- 102000018345 Chloride channel ClC-3 Human genes 0.000 claims description 7
- 108050007498 Chloride channel ClC-3 Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229940001470 psychoactive drug Drugs 0.000 claims description 6
- 239000004089 psychotropic agent Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 102000018346 Chloride channel ClC-4 Human genes 0.000 claims description 3
- 108050007495 Chloride channel ClC-4 Proteins 0.000 claims description 3
- 102000018413 Chloride channel ClC-6 Human genes 0.000 claims description 3
- 108050007501 Chloride channel ClC-6 Proteins 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 101100496114 Caenorhabditis elegans clc-2 gene Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000005062 synaptic transmission Effects 0.000 abstract description 6
- 230000028023 exocytosis Effects 0.000 abstract description 4
- 230000012202 endocytosis Effects 0.000 abstract description 3
- 230000001537 neural effect Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000506 psychotropic effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 20
- 210000002504 synaptic vesicle Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 230000020477 pH reduction Effects 0.000 description 11
- 239000000975 dye Substances 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- 102000034573 Channels Human genes 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241001484259 Lacuna Species 0.000 description 4
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 4
- 108010083204 Proton Pumps Proteins 0.000 description 4
- 201000007737 Retinal degeneration Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001159 endocytotic effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000004258 retinal degeneration Effects 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 208000002865 osteopetrosis Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 108010025996 CLC-1 channel Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000009195 Intracellular chloride channels Human genes 0.000 description 2
- 108050000080 Intracellular chloride channels Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000008826 genomic mutation Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000047411 CBS domains Human genes 0.000 description 1
- 108700037257 CBS domains Proteins 0.000 description 1
- 101100274575 Caenorhabditis elegans clh-3 gene Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 101710128223 Chloride channel protein Proteins 0.000 description 1
- 102100023461 Chloride channel protein ClC-Ka Human genes 0.000 description 1
- 101710191307 Chloride channel protein ClC-Ka Proteins 0.000 description 1
- 108010003101 ClC-3 channel Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 208000024940 Dent disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 1
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000035954 Thomsen and Becker disease Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 230000029596 acetylcholine uptake Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 101150105830 clc gene Proteins 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007309 lysosomal acidification Effects 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000034420 neuronal signal transduction Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10102977A DE10102977A1 (de) | 2001-01-23 | 2001-01-23 | Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose |
| PCT/DK2002/000038 WO2002059612A2 (en) | 2001-01-23 | 2002-01-17 | Animal model and cell-line expressing modified chlorine channel |
| AU2002224759A AU2002224759A1 (en) | 2001-01-23 | 2002-01-17 | Animal model and cell-line expressing modified chlorine channel |
| EP02715379.0A EP1360204B1 (en) | 2001-01-23 | 2002-01-17 | Process for the development of therapeutic agents, in particular active compounds for the treatment of osteoporosis |
| JP2002559678A JP4138485B2 (ja) | 2001-01-23 | 2002-01-17 | 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム |
| US10/622,377 US7534425B2 (en) | 2001-01-23 | 2003-07-18 | Animal model and cell-line expressing modified chlorine channel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10102977A DE10102977A1 (de) | 2001-01-23 | 2001-01-23 | Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10102977A1 true DE10102977A1 (de) | 2002-08-01 |
Family
ID=7671497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10102977A Pending DE10102977A1 (de) | 2001-01-23 | 2001-01-23 | Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7534425B2 (https=) |
| EP (1) | EP1360204B1 (https=) |
| JP (1) | JP4138485B2 (https=) |
| AU (1) | AU2002224759A1 (https=) |
| DE (1) | DE10102977A1 (https=) |
| WO (1) | WO2002059612A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2420830A1 (en) * | 2010-08-16 | 2012-02-22 | Forschungsverbund Berlin e.V. | Chloride transporter ClC-7 and cell-based screening method |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1360504B1 (en) * | 2001-01-23 | 2006-09-13 | Pharmos Bioscience A/S | Method for screening compounds for activity in treating an osteoclast related bone disease |
| US20030215787A1 (en) * | 2002-01-23 | 2003-11-20 | Wen-Pin Yang | Modulators of the CLC-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| AU2003214920A1 (en) | 2002-02-04 | 2003-09-02 | Millennium Pharmaceuticals Inc. | Methods and compositions for treating hematological disorders |
| GB0227243D0 (en) * | 2002-11-21 | 2002-12-31 | Univ Aberdeen | Genetic markers for bone mass |
| US7785807B2 (en) * | 2004-12-13 | 2010-08-31 | Monell Chemical Senses Center | Voltage-gated, pH-sensitive anion channel and its novel splice variant involved in taste sensation |
| WO2008101022A2 (en) * | 2007-02-13 | 2008-08-21 | The Nielsen Company (Us), Llc | Methods and apparatus to reach through to business logic services |
| US8741591B2 (en) | 2009-10-09 | 2014-06-03 | The Research Foundation For The State University Of New York | pH-insensitive glucose indicator protein |
| WO2017049178A1 (en) * | 2015-09-16 | 2017-03-23 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of making trabecular bone |
| US10640766B2 (en) * | 2017-04-12 | 2020-05-05 | Tempo Bioscience, Inc. | Biosensors for chloride ions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434058A (en) * | 1993-02-09 | 1995-07-18 | Arch Development Corporation | Apolipoprotein B MRNA editing protein compositions and methods |
| CA2305714A1 (en) * | 1997-10-01 | 1999-04-08 | Yale University | Methods to modulate blood pressure and diagnose bartter's syndrome type iii |
| OA11665A (en) | 1998-10-22 | 2004-12-08 | Neurosearch As | Substituted phenyl derivatives, their preparation and use. |
| US6686193B2 (en) * | 2000-07-10 | 2004-02-03 | Vertex Pharmaceuticals, Inc. | High throughput method and system for screening candidate compounds for activity against target ion channels |
-
2001
- 2001-01-23 DE DE10102977A patent/DE10102977A1/de active Pending
-
2002
- 2002-01-17 WO PCT/DK2002/000038 patent/WO2002059612A2/en not_active Ceased
- 2002-01-17 AU AU2002224759A patent/AU2002224759A1/en not_active Abandoned
- 2002-01-17 JP JP2002559678A patent/JP4138485B2/ja not_active Expired - Fee Related
- 2002-01-17 EP EP02715379.0A patent/EP1360204B1/en not_active Expired - Lifetime
-
2003
- 2003-07-18 US US10/622,377 patent/US7534425B2/en not_active Expired - Fee Related
Non-Patent Citations (5)
| Title |
|---|
| Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:NM_001829 * |
| Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:X83378 * |
| Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:XM_010391 * |
| Internet-Recherche am 15.10.01:wwwncbi.nlm.nih.govAccession Number:Z67744 * |
| STN-Recherche am 18.05.01 Biosis-Abstr. 1999:86968FRIEDRICK, T., BREIDERGOFF, T., JENTSCH, T.J.: Mutational analysis demonstrates that C1C-4 and C1C-5 directly mediate plasma membrane currents. 1999. In: Journal of Biological Chemestry, Vol. 274, S. 896-902 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2420830A1 (en) * | 2010-08-16 | 2012-02-22 | Forschungsverbund Berlin e.V. | Chloride transporter ClC-7 and cell-based screening method |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1360204A2 (en) | 2003-11-12 |
| WO2002059612A2 (en) | 2002-08-01 |
| WO2002059612A3 (en) | 2002-12-12 |
| JP2004531227A (ja) | 2004-10-14 |
| US20040265837A1 (en) | 2004-12-30 |
| US7534425B2 (en) | 2009-05-19 |
| JP4138485B2 (ja) | 2008-08-27 |
| EP1360204B1 (en) | 2014-04-30 |
| AU2002224759A1 (en) | 2002-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taniguchi et al. | Disruption of semaphorin III/D gene causes severe abnormality in peripheral nerve projection | |
| Young, 3rd et al. | Transgenesis and the study of expression, cellular targeting and function of oxytocin, vasopressin and their receptors | |
| DE69233477T2 (de) | Transgene nicht-menschliche tiere ohne prionprotein | |
| Strittmatter et al. | Neuronal pathfinding is abnormal in mice lacking the neuronal growth cone protein GAP-43 | |
| DE69534310T2 (de) | Ptc gene und ihre verwendung | |
| US8871996B2 (en) | Mice expressing human voltage-gated sodium channels | |
| Levine et al. | Period protein from the giant silkmoth Antheraea pernyi functions as a circadian clock element in Drosophila melanogaster | |
| US8486647B2 (en) | Neuropeptide release assay for sodium channels | |
| Periz et al. | Ca2+‐ATPase function is required for intracellular trafficking of the Notch receptor in Drosophila | |
| DE10102977A1 (de) | Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose | |
| US20090100532A1 (en) | Transgenic mice expressing hypersensitive nicotinic receptors | |
| US6753456B2 (en) | Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dopaminergic pathology and increased anxiety | |
| DE60313499T2 (de) | Mutante nichtmenschliche säuger mit sigmarezeptormangel und anwendungen dafür | |
| DE69920698T2 (de) | Transgenes nichthumanes tier mit inaktivem peg3 und dessen verwendung | |
| US20050044581A1 (en) | Animals and cells containing a mutated alpha2/omega1 gene | |
| EP2579039B1 (en) | Neuropeptide release assay for sodium channels | |
| Guo | The identification and characterization of the Drosophila GTPase dMiro and the role of presynaptic mitochondria for synaptic function | |
| WO2001068698A2 (de) | Nichtselektiver kationenkanal | |
| Dickey | Role of pp2a/bβ2 and pka/akap1 in brain development and function via dynamin-related protein 1 (drp1) control of mitochondria shape and bioenergetics | |
| Reppert et al. | Period Protein from the Giant Silkmoth Antheraea pernyi Functions as a Circadian Clock Element in Drosophila melanogaster | |
| BADEA et al. | 49 New Genetic Technologies for Studying the Morphology, Physiology, and Development of Mouse Retinal Neurons | |
| HK1178252A (en) | Neuropeptide release assay for sodium channels | |
| HK1178252B (en) | Neuropeptide release assay for sodium channels | |
| HK1185943B (en) | Neuropeptide release assay for sodium channels | |
| HK1174387B (en) | Neuropeptide release assay for sodium channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law |